Toxicology Research Today is a free monthly online journal that collates and summarizes the latest research about Toxicology, including details on forensic toxicology, carcinogenicity, assays.

Drug-eluting stents: beyond the hyperbole.

Hunter WL

Angiotech Pharmaceuticals, Inc., 1618 Station St., Vancouver, BC, Canada V6A 1B6. bhunter@angio.com

Drug-eluting stents (DES) promised to reduce the clinical and economic cost of failed bare metal stents (BMS) by locally delivering a therapeutic agent to the injured artery, reducing or eliminating the development of neointimal hyperplasia and reducing the need for repeat interventions to re-open the obstructed artery. Data from initial large-scale, comparable, U.S. pivotal trials of the first two DES to reach the American market, CYPHER from J&J using the drug rapamycin (sirolimus) and TAXUS from Boston Scientific using the drug paclitaxel (taxol), seemed to warrant the enthusiasm. By reducing the failure rate of BMS by about 4-fold, DES have changed clinical practice, reduced the rate of coronary bypass surgery, had a significant economic impact, and triggered extensive research in the areas of stent design, restenosis biology, polymeric drug-delivery and local pharmacology and toxicology.

Published 8 June 2006 in Adv Drug Deliv Rev, 58(3): 347-9.
Full-text of this article is available online (may require subscription).

© 2005-2008 Toxicology Research Today. All Rights Reserved.